Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning. Today, we look at how Bristol Myers Squibb hopes to expand schizophrenia drug Cobenfy into Alzheimer’s, and explain why psychedelics researchers who take psychedelics should disclose their psychedelics use. Also, importantly: There’s a Danish play about Novo Nordisk that I really want to see.
Bristol Myers Squibb’s gamble on Cobenfy
Bristol Myers Squibb is staking a big chunk of its future on Cobenfy, a resurrected neuroscience drug whose promise dates back to a deeply flawed Alzheimer’s trial from the 1990s. The drugmaker, STAT’s Damian Garde writes, is betting it can finally treat psychosis in Alzheimer’s disease, an area with no approved therapies and millions of patients in need.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
<
Leave a Reply